{"schema_version":"secwatch.filing_event.v1","accession":"0001818382-24-000227","form_type":"8-K","ticker":"HUMA","cik":"0001818382","company_name":"Humacyte, Inc.","filed_at":"2024-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.807670+00:00","generated_at":"2026-05-29T00:27:58.528621+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Humacyte receives FDA full approval for SYMVESS in extremity arterial injury","bullets":["FDA grants full approval for SYMVESS as a vascular conduit for extremity arterial injury when autologous vein graft is not feasible.","In clinical trials, SYMVESS showed high patency rates and low rates of amputation and infection; results published in JAMA Surgery.","Sales team already recruited and trained; commercial launch preparation is underway.","SYMVESS is a first-in-class bioengineered human tissue, available off-the-shelf, eliminating the need for vein harvest."],"urls":{"canonical":"https://secwatch.observer/filing/0001818382-24-000227","json":"https://secwatch.observer/filing/0001818382-24-000227.json","markdown":"https://secwatch.observer/filing/0001818382-24-000227.md","text":"https://secwatch.observer/filing/0001818382-24-000227.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000227/0001818382-24-000227-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000227/huma-20241219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T00:27:58.528621+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}